包装 | 价格(元) |
5mg | 电议 |
25mg | 电议 |
50mg | 电议 |
生物活性 | Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidicCXCR4antagonist with anIC50< 10 nM. Balixafortide TFA shows 1000-fold selective forCXCR4than a large panel of receptors includingCXCR7. Balixafortide TFA blocksβ-arrestinrecruitment and calcium flux with IC50s< 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects[1][2]. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | Balixafortide potently inhibits pERK / pAKT signaling in the lymphoma lines Namalwa (IC50< 200 nM) and Jurkat (IC50< 400 nM). Balixafortide efficiently blocks SDF-1 dependent chemotaxis of MDA MB 231 breast cancer cells (IC50< 20 nM), Namalwa and Jurkat cells (IC50< 10 nM)[1]. | ||||||||||||||||
体内研究 (In Vivo) | Balixafortide is optimized for favorable mouse absorption, distribution, metabolism and excretion (ADME) properties with balanced plasma protein binding, greater plasma and microsomal stability[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 1978.16 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C86H119F3N24O23S2 | ||||||||||||||||
Sequence | Cyclo(Ala-Cys-Ser-Ala-{D-Pro}-{Dab}-Arg-Tyr-Cys-Tyr-Gln-Lys-{D-Pro}-Pro-Tyr-His) (Disulfide bridge: Cys2-Cys9) | ||||||||||||||||
Sequence Shortening | Cyclo(ACSA-{D-Pro}-{Dab}-RYCYQK-{D-Pro}-PYH) (Disulfide bridge: Cys2-Cys9) | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | Sealed storage, away from moisture and light
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) | ||||||||||||||||
溶解性数据 | In Vitro: H2O : 100 mg/mL(50.55 mM;Need ultrasonic) DMSO : 100 mg/mL(50.55 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|